z-logo
Premium
Anti‐ S accharomyces cerevisiae antibody titres correlate well with disease activity in children with C rohn's disease
Author(s) -
ElMatary Wael,
Dupuis Karine,
Sokoro AbdulRazaq
Publication year - 2015
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/apa.13026
Subject(s) - medicine , antibody , crohn's disease , immunoglobulin a , immunology , disease , inflammatory bowel disease , albumin , c reactive protein , immunoglobulin g , serum albumin , univariate analysis , gastroenterology , inflammation , multivariate analysis
Aim The role of noninvasive biologic markers for disease activity is very important in children with C rohn's disease. The aim of this study was to assess an association between disease activity and quantitative serum anti‐ Saccharomyces cerevisiae antibody ( ASCA ) titres. Methods Anti‐ Saccharomyces cerevisiae antibody immunoglobulin ( I g) A and immunoglobulin G titres, paediatric C rohn's disease activity index ( PCDAI ), serum albumin and C ‐reactive protein ( CRP ) were repeatedly measured simultaneously in children with C rohn's disease. A possible association between ASCA I g A and I g G titres and changes in PCDAI was examined. Results Serial 136 measurements of ASCA I g A and I g G titres were documented in 57 children with C rohn's disease over a mean duration of 3.1 ± 2.1 years. In a univariate linear regression model, there were significant correlations between ASCA I g A titres and PCDAI (p < 0.001), CRP (p <0.01) and low serum albumin (p < 0.001), respectively. Similarly, ASCA I g G titres significantly correlated with PCDAI , CRP and low serum albumin. Conclusion Both ASCA I g A and I g G titres seemed to correlate well with clinical C rohn's disease activity in children. Measuring these antibodies may be considered during routine clinical care for those patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here